Idogen Overview

  • Founded
  • 2008
  • Status
  • Public
  • Employees
  • 9
  • Stock Symbol
Stock Symbol
  • Share Price
  • $0.36
  • (As of Tuesday Closing)

Idogen General Information


Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Other Industries
Drug Discovery
Stock Exchange
Primary Office
  • Medicon Village
  • Scheelevagen 2
  • 223 81 Lund
  • Sweden
+46 046-275 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Idogen Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.36 $0.37 $0.34 - $0.84 $6.6M 18.2M 79.9K -$0.36

Idogen Financials Summary

In Thousands,
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 1,449 749 773 5,484
Revenue 0 0 0 0
EBITDA (2,666) (2,833) (3,062) (2,486)
Net Income (2,865) (3,457) (3,176) (2,495)
Total Assets 3,665 3,336 7,974 5,397
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Idogen Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Idogen‘s full profile, request access.

Request a free trial

Idogen Executive Team (11)

Name Title Board Seat Contact Info
Ingvar Karlsson Chief Financial Officer
Åsa Schiött Ph.D Chief Scientific Officer
Hanne Romedahl Chief Scientific Officer
Neil Thomas Ph.D Chief Business Officer
Vicki Venizelos Chief Regulatory Officer
You’re viewing 5 of 11 executive team members. Get the full list »

Idogen Board Members (2)

Name Representing Role Since
0000 0000000 Self Co-Founder, Advisor & Board Member 000 0000
000000 Ø000 Ventac Partners Board Member 000 0000
To view Idogen’s complete board members history, request access »

Idogen Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Idogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Idogen‘s full profile, request access.

Request a free trial